409 Illinois Street
About FibroGen, Inc.
FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review in China by the State Drug Administration (SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
174 articles with FibroGen, Inc.
FibroGen, Inc. Announces New Research in HIF and CTGF Therapeutic Programs Presented at the Annual Meeting of the American Society of Nephrology
FibroGen, Inc. Reports Pharmacologic Stabilization Of Hypoxia-Inducible Factor (HIF) Prevents Brain Tissue Damage And Preserves Motor Function In A Preclinical Model Of Transient Ischemic Stroke
FibroGen, Inc. Reports That FG-4539, HIF-PH Inhibitor, Is Renoprotective And Improves Renal Function In Preclinical Models Of Acute Kidney Injury
FibroGen, Inc. And Shorenstein Properties Execute Build-To-Suit Construction And Long-term Lease For Mission Bay Property
FibroGen, Inc. Awarded Grant From National Heart, Lung, and Blood Institute To Develop HIF-PH Inhibitors To Treat Sickle Cell Disease
FibroGen, Inc. Announces Investigational Anti-CTGF Therapeutic, FG-3019, Reduces Tumor Growth And Metastasis In Preclinical Models Of Pancreatic Cancer
FibroGen, Inc. Licenses Oral HIF-PH Inhibitors, Including FG-2216 And FG-4592, To Astellas Pharma Inc. For The Treatment Of Anemia In Europe And Other Regions For $765 Million
FibroGen, Inc. Reports FG-4539, HIF-PH Inhibitor, Is Neuroprotective And Significantly Reduces Brain Tissue Damage In Preclinical Model Of Ischemic Stroke